Developmental stage-specific dominance of tau vs MAP6 function

Target: MAPT Composite Score: 0.550 Price: $0.51▼2.3% Citation Quality: 50% neurodegeneration Status: proposed
☰ Compare⚔ Duel⚛ Collideinteract with this hypothesis
📄 Export → LaTeX
Select venue
arXiv Preprint NeurIPS Nature Methods PLOS ONE
🌐 Open in Overleaf →
📖 Export BibTeX
✓ All Quality Gates Passed
Evidence Strength Moderate (50%)
6
Citations
1
Debates
6
Supporting
2
Opposing
Quality Report Card click to collapse
C+
Composite: 0.550
Top 56% of 1875 hypotheses
T4 Speculative
Novel AI-generated, no external validation
Needs 1+ supporting citation to reach Provisional
B Mech. Plausibility 15% 0.60 Top 57%
C+ Evidence Strength 15% 0.55 Top 47%
C+ Novelty 12% 0.55 Top 75%
C+ Feasibility 12% 0.55 Top 58%
F Impact 12% 0.00 Top 50%
F Druggability 10% 0.00 Top 50%
F Safety Profile 8% 0.00 Top 50%
F Competition 6% 0.00 Top 50%
F Data Availability 5% 0.00 Top 50%
B+ Reproducibility 5% 0.70 Top 24%
Evidence
6 supporting | 2 opposing
Citation quality: 0%
Debates
0 sessions
No debates yet
Convergence
0.00 F 30 related hypothesis share this target

Description

During early development, tau predominates to maximize plasticity and rapid axon extension; as maturation proceeds, MAP6 increasingly dominates to establish long-term stability

Prediction: The tau:MAP6 ratio on microtubules shifts progressively during development, with temporal coincidence of domain segregation correlating with developmental transitions

No AI visual card yet

Curated Mechanism Pathway

Curated pathway diagram from expert analysis

flowchart TD
    A["MAPT/Tau Protein
Microtubule Stabilizer"] B["CDK5/GSK3B Activation
Kinase Dysregulation"] C["Tau Hyperphosphorylation
Ser396/Thr231/Ser202"] D["Tau Detachment
Microtubule Destabilized"] E["Tau Oligomers
Paired Helical Filaments"] F["Neurofibrillary Tangles
Intraneuronal Inclusions"] G["Axonal Transport Failure
Synaptic Dysfunction"] H["Neurodegeneration
Tauopathy Spread"] A --> B B --> C C --> D D --> E E --> F D --> G G --> H F --> H style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7 style C fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a style H fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a

GTEx v10 Brain Expression

JSON

Median TPM across 13 brain regions for MAPT from GTEx v10.

Cerebellum209 Cerebellar Hemisphere199 Cortex152 Frontal Cortex BA9146 Anterior cingulate cortex BA24101 Hypothalamus86.4 Amygdala73.5 Nucleus accumbens basal ganglia72.2 Hippocampus72.1 Caudate basal ganglia64.7 Putamen basal ganglia58.1 Substantia nigra56.8 Spinal cord cervical c-149.2median TPM (GTEx v10)

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.
Mechanistic 0.60 (15%) Evidence 0.55 (15%) Novelty 0.55 (12%) Feasibility 0.55 (12%) Impact 0.00 (12%) Druggability 0.00 (10%) Safety 0.00 (8%) Competition 0.00 (6%) Data Avail. 0.00 (5%) Reproducible 0.70 (5%) KG Connect 0.50 (8%) 0.550 composite
8 citations 7 with PMID 7 medium Validation: 0% 6 supporting / 2 opposing
For (6)
5
2
(2) Against
High Medium Low
High Medium Low
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
3
2
3
MECH 3CLIN 2GENE 3EPID 0
ClaimStanceCategorySourceStrength ↕Year ↕Quality ↕PMIDsAbstract
Antagonistic roles of tau and MAP6 in regulating n…SupportingGENEJ Cell Sci MEDIUM2024-PMID:39257379-
Tau filaments with the Alzheimer fold in human MAP…SupportingMECHNat Struct Mol … MEDIUM2025-PMID:40044789-
MAPT mutations, tauopathy, and mechanisms of neuro…SupportingGENELab Invest MEDIUM2019-PMID:30742061-
Endolysosomal impairment by binding of amyloid bet…SupportingMECHAutophagy MEDIUM2023-PMID:36843263-
Tau-targeting antisense oligonucleotide MAPT(Rx) i…SupportingCLINNat Med MEDIUM2023-PMID:37095250-
Tau/MAP6 antagonism is shown in neuronal developme…OpposingGENEJ Cell Sci MEDIUM2024-PMID:39257379-
A microtubule-stabilizing peptide strategy failed …OpposingCLINLancet Neurol MEDIUM2014-PMID:24873720-
During early development, tau predominates to maxi…SupportingMECH------
Legacy Card View — expandable citation cards

Supporting Evidence 6

During early development, tau predominates to maximize plasticity and rapid axon extension; as maturation proc…
During early development, tau predominates to maximize plasticity and rapid axon extension; as maturation proceeds, MAP6 increasingly dominates to establish long-term stability
Antagonistic roles of tau and MAP6 in regulating neuronal development. MEDIUM
J Cell Sci · 2024 · PMID:39257379
Tau filaments with the Alzheimer fold in human MAPT mutants V337M and R406W. MEDIUM
Nat Struct Mol Biol · 2025 · PMID:40044789
MAPT mutations, tauopathy, and mechanisms of neurodegeneration. MEDIUM
Lab Invest · 2019 · PMID:30742061
Endolysosomal impairment by binding of amyloid beta or MAPT/Tau to V-ATPase and rescue via the HYAL-CD44 axis … MEDIUM
Endolysosomal impairment by binding of amyloid beta or MAPT/Tau to V-ATPase and rescue via the HYAL-CD44 axis in Alzheimer disease.
Autophagy · 2023 · PMID:36843263
Tau-targeting antisense oligonucleotide MAPT(Rx) in mild Alzheimer's disease: a phase 1b, randomized, placebo-… MEDIUM
Tau-targeting antisense oligonucleotide MAPT(Rx) in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial.
Nat Med · 2023 · PMID:37095250

Opposing Evidence 2

Tau/MAP6 antagonism is shown in neuronal development models, but this does not establish that the same balance… MEDIUM
Tau/MAP6 antagonism is shown in neuronal development models, but this does not establish that the same balance drives adult neurodegeneration progression or treatment response.
J Cell Sci · 2024 · PMID:39257379
A microtubule-stabilizing peptide strategy failed to show clinical benefit in progressive supranuclear palsy, … MEDIUM
A microtubule-stabilizing peptide strategy failed to show clinical benefit in progressive supranuclear palsy, cautioning against simple cytoskeletal-stabilization translation in tauopathy.
Lancet Neurol · 2014 · PMID:24873720
Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.

No linked debates yet. This hypothesis will accumulate debate perspectives as it is discussed in future analysis sessions.

Price History

0.500.530.55 0.57 0.48 2026-04-252026-04-262026-04-27 Market PriceScoreevidencedebate 7 events
7d Trend
Stable
7d Momentum
▼ 2.3%
Volatility
High
0.0544
Events (7d)
7

Clinical Trials (5) Relevance: 65%

0
Active
0
Completed
0
Total Enrolled
PHASE1
Highest Phase
Continuation of The Kronos Early Estrogen Prevention Study (KEEPS) Unknown
COMPLETED · NCT03718494 · Mayo Clinic
Alzheimer Dementia
Brain Magnetic Resonance Imaging (MRI) F-18 Florbetapir Positron Emission Tomography (PET) Imaging F-18 AV-1451 Positron Emission Tomography (PET) Imaging
An Extension Study to Evaluate the Long-Term Safety and Tolerability of JNJ-54861911 in Participants in the Early Alzheimer's Disease Spectrum PHASE2
TERMINATED · NCT02406027 · Janssen Research & Development, LLC
Alzheimer Disease
JNJ-54861911, 10 mg JNJ-54861911, 25 mg Placebo
Activity of Cerebral Networks, Amyloid and Microglia in Aging and Alzheimer's Disease Unknown
COMPLETED · NCT06224920 · Ludwig-Maximilians - University of Munich
Alzheimer Disease Corticobasal Syndrome
magnetic resonance imaging electroencephalography blood and CSF biomarker
Clinical Safety and Efficacy Evaluation of NanoLithium® NP03 in Patients With Mild-to-severe Alzheimer's Disease PHASE2
COMPLETED · NCT05423522 · Medesis Pharma SA
Alzheimer's Disease
NanoLithium® NP03 Placebo
A Noval Tau Tracer in Young Onset Dementia PHASE1
UNKNOWN · NCT04248270 · Chang Gung Memorial Hospital
Alzheimer's Disease Vascular Dementia Dementia
18F-PM-PBB3

📚 Cited Papers (6)

No extracted figures yet
MAPT mutations, tauopathy, and mechanisms of neurodegeneration.
Laboratory investigation; a journal of technical methods and pathology (2019) · PMID:30742061
No extracted figures yet
No extracted figures yet
No extracted figures yet
No extracted figures yet
Tau filaments with the Alzheimer fold in human MAPT mutants V337M and R406W.
Nature structural & molecular biology (2025) · PMID:40044789
No extracted figures yet

📅 Citation Freshness Audit

Freshness score = exp(-age×ln2/5): halves every 5 years. Green >0.6, Amber 0.3–0.6, Red <0.3.

No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.

📙 Related Wiki Pages (0)

No wiki pages linked to this hypothesis yet.

࢐ Browse all wiki pages

📓 Linked Notebooks (0)

No notebooks linked to this analysis yet. Notebooks are generated when Forge tools run analyses.

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas
→ Browse all arenas & tournaments

📊 Resource Economics & ROI

Moderate Efficiency Resource Efficiency Score
0.50
32.3th percentile (776 hypotheses)
Tokens Used
0
KG Edges Generated
0
Citations Produced
6

Cost Ratios

Cost per KG Edge
0.00 tokens
Lower is better (baseline: 2000)
Cost per Citation
0.00 tokens
Lower is better (baseline: 1000)
Cost per Score Point
0.00 tokens
Tokens / composite_score

Score Impact

Efficiency Boost to Composite
+0.050
10% weight of efficiency score
Adjusted Composite
0.600

How Economics Pricing Works

Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.

High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.

Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.

Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.

📋 Reviews View all →

Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.

💬 Discussion

No DepMap CRISPR Chronos data found for MAPT.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for MAPT →
Loading history…

⚖️ Governance History

No governance decisions recorded for this hypothesis.

Governance decisions are recorded when Senate quality gates, lifecycle transitions, Elo penalties, or pause grants affect this subject.

Browse all governance decisions →

Related Hypotheses

Glymphatic-Mediated Tau Clearance Dysfunction
Score: 0.865 | neuroscience
Dual-Circuit Tau Vulnerability Cascade
Score: 0.774 | neuroscience
Cholinergic Basal Forebrain-Hippocampal Circuit Protection
Score: 0.760 | neuroscience
Repeat-domain exposure defines seed-competent tau conformers
Score: 0.760 | neurodegeneration
Dopaminergic Ventral Tegmental-Hippocampal Circuit Protection
Score: 0.751 | neuroscience

Estimated Development

Estimated Cost
$0
Timeline
0 months

🧪 Falsifiable Predictions (2)

2 total 0 confirmed 0 falsified
IF we measure tau and MAP6 protein levels on assembled microtubules across postnatal development in mice (E18, P7, P14, P30, P90), THEN the tau:MAP6 ratio on microtubules will decrease progressively by approximately 50-70% from early (E18-P7) to mature (P30-P90) stages.
pending conf: 0.70
Expected outcome: Progressive decrease in tau:MAP6 ratio on microtubule fraction; tau levels decline while MAP6 levels increase
Falsified by: The tau:MAP6 ratio remains constant or increases during development, contradicting the predicted shift toward MAP6 dominance
Method: Western blot quantification of microtubule-bound vs. soluble fractions from mouse cortical/hippocampal tissue at five developmental timepoints (n=6 per stage)
IF we perform tau knockdown in cultured hippocampal neurons derived from early postnatal mice (P0-P2) versus mature mice (P21-P28), THEN overexpression of MAP6 will fully rescue axon extension defects in mature neurons but only partially in early neurons, while tau overexpression will show the opposite pattern.
pending conf: 0.65
Expected outcome: At P0-P2 neurons: tau rescue >80% of control axon length, MAP6 rescue <40%. At P21-P28 neurons: MAP6 rescue >80% of control axon length, tau rescue <40%
Falsified by: Both tau and MAP6 rescue axon extension equally at both developmental stages, indicating functional redundancy without temporal specificity
Method: Primary hippocampal neuron cultures from two age groups, transfected with tau siRNA or MAP6 siRNA followed by AAV-mediated overexpression of the complementary protein; axon length quantified after 3 days in vitro via MAP2 immunostaining

Knowledge Subgraph (0 edges)

No knowledge graph edges recorded

3D Protein Structure

🧬 MAPT — PDB 5O3L Click to expand 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll | Reset: right-click

Community Feedback

0 0 upvotes · 0 downvotes
💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

Same Analysis (2)

Tau/MAP6 ratio as a master switch for microtubule dynamics plasticity
Score: 0.75 · MAPT
Tau/MAP6 antagonism in neurodegeneration progression
Score: 0.65 · MAP6
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.